On the intrinsic reactivity of highly potent trypanocidal cruzain inhibitors.
Vinicius Bonatto, Pedro Henrique Jatai Batista, Lorenzo Cianni, Daniela De Vita, Daniel G Silva, Rodrigo Cedron, Daiane Y Tezuka, Sérgio de Albuquerque, Carolina Borsoi Moraes, Caio Haddad Franco and 3 more
Article in RSC medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 10 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 3 institutions in 3 countries.
Vinicius BonattoMedicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo Avenue Trabalhador Sancarlense, 400 23566-590 São Carlos/SP Brazil andreileitao@iqsc.usp.br carlos.montanari@usp.br.
Pedro Henrique Jatai BatistaMedicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo Avenue Trabalhador Sancarlense, 400 23566-590 São Carlos/SP Brazil andreileitao@iqsc.usp.br carlos.montanari@usp.br.
Lorenzo CianniMedicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo Avenue Trabalhador Sancarlense, 400 23566-590 São Carlos/SP Brazil andreileitao@iqsc.usp.br carlos.montanari@usp.br.
Daniela De VitaMedicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo Avenue Trabalhador Sancarlense, 400 23566-590 São Carlos/SP Brazil andreileitao@iqsc.usp.br carlos.montanari@usp.br.
Daniel G SilvaMedicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo Avenue Trabalhador Sancarlense, 400 23566-590 São Carlos/SP Brazil andreileitao@iqsc.usp.br carlos.montanari@usp.br.
Rodrigo CedronMedicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo Avenue Trabalhador Sancarlense, 400 23566-590 São Carlos/SP Brazil andreileitao@iqsc.usp.br carlos.montanari@usp.br.
Daiane Y TezukaMedicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo Avenue Trabalhador Sancarlense, 400 23566-590 São Carlos/SP Brazil andreileitao@iqsc.usp.br carlos.montanari@usp.br.
Sérgio de AlbuquerqueRibeirão Preto School of Pharmaceutical Sciences, University of São Paulo Ribeirão Preto São Paulo Brazil.
Carolina Borsoi MoraesLaboratório Nacional de Biociências (LNBio), Centro Nacional de Pesquisa em Energia e Materiais (CNPEM) Campinas São Paulo Brazil.
Caio Haddad FrancoLaboratório Nacional de Biociências (LNBio), Centro Nacional de Pesquisa em Energia e Materiais (CNPEM) Campinas São Paulo Brazil.ORCID https://orcid.org/0000-0003-2467-9401
Jerônimo LameiraMedicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo Avenue Trabalhador Sancarlense, 400 23566-590 São Carlos/SP Brazil andreileitao@iqsc.usp.br carlos.montanari@usp.br.ORCID https://orcid.org/0000-0001-7270-1517
Andrei LeitãoMedicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo Avenue Trabalhador Sancarlense, 400 23566-590 São Carlos/SP Brazil andreileitao@iqsc.usp.br carlos.montanari@usp.br.ORCID https://orcid.org/0000-0002-6601-6609
Carlos A MontanariMedicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo Avenue Trabalhador Sancarlense, 400 23566-590 São Carlos/SP Brazil andreileitao@iqsc.usp.br carlos.montanari@usp.br.ORCID https://orcid.org/0000-0002-4963-0316
Medicina · PLLaboratório Nacional de Ciência e Tecnologia do Bioetanol · BRClinics Hospital of Ribeirão Preto · BR
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The cysteine protease cruzipain is considered to be a validated target for therapeutic intervention in the treatment of Chagas disease. Hence, peptidomimetic cruzipain inhibitors having a reactive group (known as warhead) are subject to continuous studies to discover novel antichagasic compounds. Here, we evaluated how different warheads for a set of structurally similar related compounds could inhibit the activity of cruzipain and, ultimately, their trypanocidal effect. We first investigated
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
On the intrinsic reactivity of highly potent trypanocidal cruzain inhibitors. · full record | OpenQuestion